Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: Navigating between Scylla and Charybdis

Expert Opinion on Emerging Drugs

Volumn 19, Issue 1, 2014, Pages 5-9

  Machado, Ubiratan Fabres ^a   Corrêa Giannella, Maria Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Glycemic control; Glycosuria; SGLT1; SGLT2; Sodium glucose cotransporter

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; NEW DRUG; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; TOFOGLIFLOZIN; UNCLASSIFIED DRUG;

AMINOACIDURIA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERTRANSAMINASEMIA; META ANALYSIS (TOPIC); NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL COUNSELING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOXIC HEPATITIS; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84896718396     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2014.875530     Document Type: Review

References (21)

1. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-18
2. Sabino-Silva R, Mori RC, David-Silva A, et al. The Na+/glucose cotransporters: from genes to therapy. Braz J Med Biol Res 2010;43:1019-26 . A comprehensive review of SGLTs.
3. Freitas HS, Anhê GF, Melo KF, et al. Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008;149:717-24
4. da Silva AS, Dias LD, Borges JF, et al. Renal GLUT1 reduction depends on angiotensin-converting enzyme inhibition in diabetic hypertensive rats. Life Sci 2013;92:1174-9
5. Wright EM, Turk E, Martin MG. Molecular basis for glucose-galactose malabsorption. Cell Biochem Biophys 2002;36:115-21
6. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5(1):133-41
7. Freitas HS, D'Agord Schaan B, da Silva RS, et al. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats. Nephron Physiol 2007;105:42-51
8. Boyle LD, Wilding JP. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. Expert Opin Emerg Drugs 2013;18:375-91
9. FDA Advisory Committee Meeting. FDA Briefing Document. NDA 202293 (Dapagliflozin Tablets, 5 mg and 10 mg. Sponsor: Bristol-Myers Squibb). 2011. Available from: http://www.fda.gov/downloads/Advisory Committees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/ucm262994.pdf [Accessed 3 September 2013]
10. FDA Advisory Committee Meeting. FDA Briefing Document. NDA 204042 (Invokana (canagliflozin) Tablets. Applicant: Janssen Pharmaceuticals, Inc.). 2013. Available from: http://www.fda. gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugs AdvisoryCommittee/UCM334550.pdf [Accessed 3 September 2013]
11. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375-93
12. Demaris KM, White Jr. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2013;49:289-301 . Remarkable review of dapagliflozin.
13. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012;92:158-69
14. Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia. Obesity 2012;20:1645-52
15. Donders GG. Lower genital tract infections in diabetic women. Curr Infect Dis Rep 2002;4:536-9
16. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74
17. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-84
18. Ly JP, Onay T, Sison K, et al. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 2011;22:113-23
19. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013;62:3324-8
20. Marks J, Carvou NJ, Debnam ES, et al. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 2003;553(Pt 1):137-45
21. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61